Цілеспрямований синтез потенційних протипухлинних субстанцій в ряду похідних 3-меркапто-4-(1Н-пірол-1-іл)-5-циклогексил-1,2,4-триазолу(4H)

• Видавець: National University of Pharmacy
• Дата: 2014
• Автори: Saidov, N. B., Georgiyants, V. A., Demchenko, A. M.
• Формат: Стаття
• Мова: English
• Опубліковано: National University of Pharmacy 2014
• Теми: 3-mercapto-1; 2; 4-triazole; pyrrole; derivatives; synthesis; antitumor action; UDC 54.057; 547.792; 3-меркапто-1; 4-триазол; пиррол; производные; синтез; противоопухолевое действие; УДК 54.057; пірол; похідні; протипухлинна дія
• Онлайн доступ: https://ophcj.nuph.edu.ua/article/view/ophcj.14.781

Synthesis of the series of new 4-(1H-pyrrol-1-yl)-5-cyclohexyl-1,2,4-triazole(4H)-3-yl thioacetanilides from 4-amino-5-cyclohexyl-1,2,4-triazole(4H)-3-yl thioacetanilides previously synthesized is described. The target products 3a-z have been obtained by Paal-Knorre pyrrole condensation of the initial aminocompounds 1 with 2,5-dimethoxytetrahydrofuran (2) in the acetic acid medium. The structure of the substances synthesized has been proven by elemental analysis and NMR spectra data. All compounds synthesized contain signals of the cyclohexane system protons as two multiplets in their NMR spectra at 2.39-2.33 ppm (methyne proton) and 1.76-1.13 ppm (cyclohexyl methylene groups protons). Unlike the starting compounds (1) the end products (3a-z) have no signal of 4-aminogroup proton as a singlet in the spectra at 5.87-5.92 ppm. Instead of it, signals of the pyrrole ring are present as two triplets at 7-20-7.17 and 6.32-6.29 ppm. Among activities being more probable for the substances synthesized due to preliminary PASS-prognosis were inhibition of MAO and some enzymes (Pa = 0.554-0.729). Compound (3w) was selected by the National Cancer Institute (NCI) for in vitro screening on different tumour cell lines. As result of this investigation we have noted that, unfortunately, substance 3w is not an effective inhibitor of tumour cells in the dose studied, in particular the growth percent for leukemia cells for more sensitive lines is 68.48 (RPMI-8226); 69.30 (HL-60(TB)); for non-small cell lung cancer – 63.06 (HOP-92); for melanoma – 47.82 (SK-MEL-5); 67.37 (UACC-62); for renal cancer – 56.66 (UO-31). Sensitivity of all cancer cell lines for the colon, CNS, ovarian, prostate and breast cancer was approximately at the control level.